Epigenetics is defined as heritable changes in gene expression mediated mostly by DNA methylation and histone tail modifications without changes in DNA sequence.^[@bib1]^ Epigenetic abnormalities in cancer lead to reprogramming of gene expression resembling embryonic stem cells, loss of tumor suppressors, or reactivation of oncofetal genes.^[@bib2],\ [@bib3]^ For example, enhanced histone 3 lysine 27 trimethylation (H3K27me3), mediated by a complex of proteins, including the histone methyltransferase EZH2, causes the silencing of tumor-suppressor genes.^[@bib4],\ [@bib5]^

Similar to H3K27me3, histone 3 lysine 36 trimethylation (H3K36me3) has a diverse role in chromatin structure and function.^[@bib6]^ H3K36me3 regulates transcription of active euchromatin, alternative splicing, DNA repair, and transmission of the memory of gene expression from parents to offspring.^[@bib7]^ At least eight enzymes methylate H3K36. Nuclear receptor-binding SET domain protein 1 (NSD1; lysine methyltransferases 3B (KMT3B)) and NSD2 are involved in monomethylation and dimethylation, whereas SET domain containing 2 (SETD2; KMT3A) trimethylates H3K36.^[@bib6]^ However, depletion of NSD1 in certain cells leads to loss of H3K36me3 and altered gene expression.^[@bib8],\ [@bib9]^

NSD1 functions as a tumor suppressor in several cancers. For example, epigenetic silencing of NSD1 is observed in neuroblastoma.^[@bib9]^ NSD1 mutation/deletion is observed in bladder cancer.^[@bib10]^ NSD1 is one of the genes essential for anti-estrogen sensitivity in breast cancer.^[@bib11]^ NSD1 is also described as an oncogene in acute myeloid leukemia in which a chromosomal translocation creates nucleoporin 98 kDa (NUP98):NSD1 fusion protein, and the expression is driven by NUP98 regulatory elements.^[@bib12]^ NSD2 is an oncogene, whereas SETD2 is inactivated through mutation/deletion in multiple cancers.^[@bib10],\ [@bib13],\ [@bib14]^ Interestingly, H3K36me3 and H3K27me3 on a gene may be mutually exclusive, suggesting distinct role of modulators of these modifications on gene expression.^[@bib15]^

Loss of histone 4 lysine 20 trimethylation (H4K20me3) is a hallmark of cancer.^[@bib16]^ The histone methyltransferases KMT5B (SUV4-20H1) and KMT5C (SUV4-20H2) mediate histone H4K20me3, whereas PHD finger protein 2 (PHF2) demethylates this residue.^[@bib17],\ [@bib18]^ NSD1 is also reported to trimethylate H4K20.^[@bib9]^ H4K20me3 is necessary for the repressive pathway that induce pericentric heterochromatin required for G2/M arrest in response to DNA damage and recruitment of DNA repair complex.^[@bib17],\ [@bib19]^ In addition, loss of H4K20me3 is associated with telomere elongation and derepression of telomere recombination.^[@bib20]^ Depletion of KMT5B or KMT5C leads to increased telomere elongation, which is common in cancer.^[@bib20]^

Developing drugs that reverse cancer-specific histone modifications is one of our goals. Towards this end, we targeted the transcription factor nuclear factor-kappaB (NF-*κ*B), which is activated in cancers and regulates inflammation-associated epigenetic changes.^[@bib21],\ [@bib22]^ Using pharmacological and genomic approaches, we show upregulation of NSD1 and SETD2 upon NF-*κ*B inhibition. Dimethylaminoparthenolide (DMAPT), the pharmacological inhibitor of NF-*κ*B, additionally increased KMT5C and H4K20me3 independent of its NF-*κ*B inhibition attribute.

Results
=======

The effects of DMAPT on histone modifications
---------------------------------------------

Parthenolide, an NF-*κ*B inhibitor, reduces histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1 independent of NF-*κ*B inhibition.^[@bib23],\ [@bib24]^ However, it is unclear whether parthenolide alters NF-*κ*B-dependent epigenetic changes that are observed in inflammation.^[@bib22]^ To test this possibility, we examined the effect of dimethylaminoparthenolide (DMAPT), a water-soluble analog of parthenolide,^[@bib25]^ on the expression of histone-modifying enzymes and on histone modifications. The study was initiated in bladder cancer cell lines UMUC-3 and RT-4 because of our previous report showing DMAPT-mediated cell cycle arrest and apoptosis of UMUC-3 cells *in vitro* and inhibition of tumor growth in xenograft models.^[@bib25]^ DMAPT reduced the levels of HDAC-1 in UMUC-3 cells but had a modest effect in RT-4 cells ([Figure 1a](#fig1){ref-type="fig"}). DMAPT reduced EZH2 and C-terminal-binding protein 1 (CtBP1) more efficiently in UMUC-3 cells compared with RT-4 cells. In contrast, the effect of DMAPT on poly-(ADP-ribose) polymerase (PARP)-1 was more pronounced in RT-4 cells. These changes in histone-modifying enzyme levels correlated with an increase in the levels of p21 and pro-apoptotic BIM ([Figure 1b](#fig1){ref-type="fig"}). It is unlikely that the effect of DMAPT on the above proteins is due to genotoxic stress/DNA-damage response, because DMAPT did not alter TIP60 (histone acetyltransferase Tip60) levels, which is typically activated upon double-stranded DNA break^[@bib26]^ ([Figure 1a](#fig1){ref-type="fig"}).

We next determined the effects of DMAPT on histone H3 and H4 modifications. DMAPT increased the levels of H3K36me3 by 1.6--2.5-fold, although the induction was transient in UMUC-3 cells ([Figure 1c](#fig1){ref-type="fig"}). Increase in H3K36me3 was accompanied with decrease in H3K27me3 in RT-4 cells only, despite DMAPT reducing EZH2 levels in both cell types. Overall, DMAPT displayed higher effect on epigenetic machinery in RT-4 cells compared with UMUC-3 cells.

With respect to histone H4, DMAPT increased H4K20me3 by 2.8--16-fold ([Figure 1c](#fig1){ref-type="fig"}). H4K8 acetylation was modestly lower in DMAPT-treated cells, although this change was observed only after 24 h of treatment. H4K8 acetylation is usually an inflammatory response mediated by NF-*κ*B, and the effect of DMAPT on this acetylation is consistent with its ability to inhibit NF-*κ*B.^[@bib27]^ Among various histone modifications examined, H3K36me3 and H4K20me3 were consistently elevated in DMAPT-treated cells.

NF-*κ*B inhibition through genomic approaches results in elevated H3K36me3
--------------------------------------------------------------------------

We used two model systems to determine which among the activities of DMAPT described above can be recapitulated through genomic inhibition of NF-*κ*B. The first model system involved overexpression of inhibitor-of-kappaB alpha super-repressor (I*κ*B*α*SR), and the second approach utilized mouse embryonic fibroblasts (MEFs) lacking the p65 subunit of NF-*κ*B.^[@bib28],\ [@bib29]^ Unfortunately, UMUC-3 cells overexpressing I*κ*B*α*SR could not be maintained for a prolonged time. We had previously demonstrated feasibility of generating MDA-MB-231 breast cancer cells overexpressing I*κ*B*α*SR.^[@bib28]^ MDA-MB-231 cells have constitutively active NF-*κ*B, and I*κ*B*α*SR reduced basal and tumor necrosis factor alpha (TNF*α*)-inducible activation of NF-*κ*B ([Figure 2a](#fig2){ref-type="fig"}). P65−/− MEFs lack p65 DNA-binding activity but displayed p50 and c-Rel DNA-binding activity as evident from antibody supershift assay ([Figure 2a](#fig2){ref-type="fig"}, compare lanes 6 with 8, 15 with 19, and 12 with 20).

Basal H3K36me3 was 1.8-fold higher in I*κ*B*α*SR cells compared with parental cells, which coincided with lower H3K36 dimethylation ([Figure 2b](#fig2){ref-type="fig"}). These results suggest that NF-*κ*B inhibition through genomic approaches can recapitulate the effects of DMAPT on H3K36me3. The effect of DMAPT on H4K20me3 in MDA-MB-231 cells was not as robust as in UMUC-3 cells, suggesting cell type specificity ([Figure 2b](#fig2){ref-type="fig"}).

We next examined wild-type and p65−/− MEFs for histone modifications. Basal H3K36me3 was 2-fold higher in p65−/− cells compared with wild-type cells ([Figure 2c](#fig2){ref-type="fig"}). Interestingly, DMAPT significantly increased H4K20me3 in wild-type but not in p65−/− cells. In addition, basal H4K20me3 levels were the same in wild-type and p65−/− cells. Reasons for this discrepancy are unknown.

DMAPT treatment or NF-*κ*B inhibition results in elevated NSD1 and SETD2
------------------------------------------------------------------------

To determine the targets of DMAPT that are responsible for histone H3K36me3, we measured the levels of NSD1, NSD2, and SETD2. DMAPT increased the expression of NSD1 in both RT-4 and UMUC-3 cells ([Figure 3a](#fig3){ref-type="fig"}). Highest induction was observed in RT-4 cells (2.6-fold), which also showed persistent elevation of H3K36me3 upon DMAPT treatment.

To obtain definitive evidence for the negative regulation of NSD1 expression by NF-*κ*B, we measured NSD1 in MDA-MB-231 cells overexpressing I*κ*B*α*SR and p65−/− MEFs. DMAPT increased NSD1 in MDA-MB-231 and wild-type MEFs although the level of induction was not as high as in RT-4 cells ([Figure 3a](#fig3){ref-type="fig"}). Basal expression of NSD1 was 2.1-fold higher in p65−/− cells compared with wild-type cells confirming that inhibition of canonical NF-*κ*B results in elevated NSD1. DMAPT treatment or I*κ*B*α*SR overexpression had negligible effect on NSD2 levels ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}).

Similar to NSD1, SETD2 was responsive to DMAPT treatment or NF-*κ*B inhibition through genomic approaches, although the degree of response was lower and was cell type-specific ([Figure 3b](#fig3){ref-type="fig"}). Critically, basal SETD2 levels were higher in p65−/− cells (\~2-fold) compared with wild-type cells, demonstrating an effect of NF-*κ*B on its expression.

To ensure that DMAPT treatment or NF-*κ*B inhibition leads to elevated NSD1 and SETD2 proteins, western blotting was performed. One set of antibodies among many tested recognized proteins of expected size (\~300 kDa) and were reactive against only murine proteins. Basal NSD1 and SETD2 levels were higher in untreated p65−/− MEFs compared with wild-type MEFs ([Figure 3c](#fig3){ref-type="fig"}). DMAPT increased NSD1 protein in wild-type MEFs. In contrast, SETD2 protein levels were higher in DMAPT-treated wild-type and p65−/− cells. It appears that cell confluency impacts basal NSD1 and SETD2 levels, as the basal expression was lower in untreated cells plated for 24 h compared with cells plated for 12 h.

Although NF-*κ*B predominantly increases the expression of genes, it represses few genes,^[@bib30],\ [@bib31],\ [@bib32]^ and this study adds NSD1 and SETD2 to the list of NF-*κ*B repressed genes. To ensure that induction of NSD1 and SETD2 by DMAPT is not due to a global positive effect of DMAPT on transcription, we measured the effect of DMAPT on the expression of NF-*κ*B-inducible CXCL1.^[@bib33]^ DMAPT reduced the level of CXCL1 in both UMUC-3 and RT-4 cells ([Figure 3d](#fig3){ref-type="fig"}), confirming the specificity in the effects of DMAPT on NSD1 and SETD2.

To further demonstrate the negative relationship between NF-*κ*B and NSD1, we transfected p65−/− cells with a constitutively active p65 subunit of NF-*κ*B in which nuclear localization signal of p65 has been replaced with that of p50 subunit (p65NLS50).^[@bib34]^ P65−/− cells transfected with p65NLS50 showed lower levels of NSD1 but not SETD2 ([Figure 3e](#fig3){ref-type="fig"}). The reason for the lack of effects of p65NLS50 on SETD2 is unknown. H3K36me3 but not H4K20Me3 levels were lower in p65NLS50-transfected cells compared with the vector-transfected cells ([Figure 3f](#fig3){ref-type="fig"}), demonstrating the existence of an NF-*κ*B:NSD1:H3K36me3 axis.

To correlate the effect of DMAPT on NSD1 and H3K36me3 on cellular phenotype, we subjected untreated and DMAPT-treated wild-type and p65−/− MEFs to western blotting analysis for PARP-1 and apoptosis assay using Annexin V labeling. DMAPT reduced the levels of PARP-1 ([Figure 3g](#fig3){ref-type="fig"}) and induced apoptosis ([Figure 3h](#fig3){ref-type="fig"}) in wild-type but not p65−/− cells. Resistance of p65−/− cells to DMAPT-induced apoptosis is surprising, considering that these cells have higher basal levels of NSD1. One possibility is that, in the absence of p65, cells adapt to alternative survival mode, and inducible/acute suppression of NF-*κ*B activity is required to evoke apoptotic response. We could not efficiently reduce NSD1 in these cells by siRNA owing to poor transfection efficiency, which prevented us from confirming the role of DMAPT-induced NSD1 in apoptosis.

DMAPT increases the expression of KMT5C (SUV4-20H2) in a cell type-dependent manner
-----------------------------------------------------------------------------------

As noted in [Figure 1](#fig1){ref-type="fig"}, DMAPT increased H4K20me3 although this induction appeared to be NF-*κ*B-independent, because p65−/− cells did not display elevated levels of H4K20me3 ([Figure 2](#fig2){ref-type="fig"}). KMT5C/SUV4-20H2 is one of the methyltransferases involved in this trimethylation.^[@bib35]^ DMAPT increased the expression of KMT5C consistently in RT-4, UMUC-3, and MDA-MB-231 cells ([Figure 4a](#fig4){ref-type="fig"}). However, there was marked experimental variability in the effect of DMAPT on KMT5C expression in MEFs (induction in two out of the three experiments in wild-type but not p65−/− MEFs, [Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}). Moreover, I*κ*B*α*SR overexpression in MDA-MB-231 cells did not lead to elevated KMT5C expression. Based on these results, we conclude that DMAPT induces KMT5C in a cell type-dependent but NF-*κ*B-independent manner. In this regard, DMAPT induces c-Jun N-terminal kinase (JNK) and generates of reactive oxygen species independent of NF-*κ*B inhibition.^[@bib25]^

H3K36 demethylases are not the targets of DMAPT
-----------------------------------------------

Previous studies have demonstrated that lysine demethylases 2A (KDM2A; FBXL11) and KDM2B (FBXL10) demethylate monomethylated and dimethylated H3K36, whereas KDM4A, KDM4B, KDM4C, KDM4D, and NO66 demethylate H3K36 dimethyl and trimethyl moieties.^[@bib36]^ Additionally, independent studies have demonstrated that NSD1, NF-*κ*B, and KDM2A form a feedback axis in which NSD1 methylates p65 subunit and activates NF-*κ*B, which leads to elevated expression of KDM2A.^[@bib37]^ KDM2A in turn demethylates and inactivates NF-*κ*B. KDM2B is also an NF-*κ*B-inducible gene.^[@bib38]^ As NF-*κ*B inhibited NSD1 expression, we next examined the effect of DMAPT or I*κ*B*α*SR overexpression on the expression of KDMs associated with demethylation of H3K36me3. KDM2B showed a distinct pattern of expression upon pharmacological or genetic inhibition of NF-*κ*B ([Figure 4b](#fig4){ref-type="fig"}). DMAPT treatment did not alter KDM2B in MDA-MB-231 cells. However, I*κ*B*α*SR overexpression reduced its basal expression consistent with reported NF-*κ*B-inducible expression of this gene.^[@bib38]^ Interestingly, wild-type and p65−/− MEFs showed similar levels of KDM2B and DMAPT had no effect on its expression, which suggests cell type-specific requirement of NF-*κ*B for its expression. Lack of effect of DMAPT on its expression is intriguing, which could be due to competing signaling pathways activated/repressed by DMAPT compensating for the loss of NF-*κ*B activity. In this respect, we had previously demonstrated the ability of DMAPT or parthenolide to induce JNK independent of NF-*κ*B inhibition.^[@bib25],\ [@bib39]^ Note that I*κ*B*α*SR overexpression did not have an effect on KDM4A and KDM4B expression, although DMAPT modestly increased their expression, which could be an off-target effect or a non-specific response of cells to drug treatment ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}). Overall, these results favor the possibility that increase in KMTs rather than reduced levels of KDMs contribute to H3K36 trimethylation in DMAPT-treated cells. The effect of DMAPT treatment, I*κ*B*α*SR overexpression, or p65 deletion on epigenetic markers and the expression of epigenetic modulators are summarized in [Table 1](#tbl1){ref-type="table"}.

NSD1 is essential for DMAPT-induced BIM expression
--------------------------------------------------

To determine whether NSD1 and SETD2 have any role in DMAPT-induced BIM and p21 expression, we examined the effects of siRNA against NSD1 and SETD2 on their expression in UMUC-3 cells. SiRNA against NSD1 but not SETD2 prevented DMAPT-induced BIM and p21 expression ([Figure 5a](#fig5){ref-type="fig"}). For unknown reason, we observed elevated basal p21 in NSD1 siRNA-treated cells. Because of the transfection-induced stress, we consistently observed lower p21 and BIM induction by DMAPT under this experimental condition. siRNAs were effective in reducing the levels of target gene mRNAs ([Figure 5b](#fig5){ref-type="fig"}). We were unable to reproducibly detect the effects of NSD1 and SETD2 siRNA on basal and/or DMAPT-induced H3K36me3 (except in MCF-7 cells) or H4K20me3.

We next examined whether NSD1 and SETD2 are required for DMAPT-induced growth inhibition. Cells transfected with SETD2 siRNA but not NSD1 siRNA were partially resistant to DMAPT compared with control siRNA-transfected cells ([Figure 5c](#fig5){ref-type="fig"}).

NSD1 and SETD2 expression in bladder and breast cancer
------------------------------------------------------

Analysis of the public database cBioportal revealed significant mutations/deletion of NSD1 and SETD2 in multiple cancers, including bladder cancer ([www.cbioportal.org](http://www.cbioportal.org)).^[@bib40],\ [@bib41]^ In The Cancer Genome Atlas (TCGA) bladder data set (*n*=127), 8% of cases showed deletions, amplification, and/or mutation of NSD1. One percent of breast cancers showed NSD1 alterations (*n*=482). Mutation, amplification, and/or deletion of SETD2 were observed in 10% of bladder cancer (*n*=127). SETD2 alterations were found in 1% of breast cancer (*n*=482). Across multiple cancers, most of the SETD2 alterations involved mutations and deletions but rarely amplification. To determine whether the expression levels of these two genes have diagnostic/prognostic impact, we queried public gene expression databases. In one of the bladder cancer data set in gene expression omnibus (GEO),^[@bib42]^ we observed significant reduction in NSD1 expression in non-muscle invasive urothelial cancer with or without carcinoma *in situ* and mucosa invasive carcinoma but not in carcinoma *in situ* compared with normal urothelium ([Figure 6a](#fig6){ref-type="fig"}). Oncomine search revealed copy number loss and reduced mRNA levels in various bladder cancer stages ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). In contrast to NSD1, SETD2 expression levels did not show any correlation with disease stage. In fact, its expression was elevated in urothelial cancer with carcinoma *in situ* and mucosa invasive carcinoma but not in carcinoma *in situ* cases or cancer without carcinoma *in situ* compared with normal urothelium ([Figure 6b](#fig6){ref-type="fig"}). In addition, Oncomine database search did not reveal bladder cancer tumor stage-specific changes in SETD2 expression. However, comparison of SETD2 expression across several cancers demonstrated lower SETD2 expression in multiple cancers, including bladder cancer (fold changes −2.3 and −3 in two studies) ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

We recently developed an online tool, which enables investigators to determine the prognostic value of genes in \>20 data sets with clinical annotation.^[@bib43]^ With the TCGA breast cancer data set, higher expression of NSD1 showed a trend toward better overall survival when all tumor subtypes were considered ([Figure 6c](#fig6){ref-type="fig"}) and significant survival advantage in HER2-negative patients (135 high and 134 low expression cases, [Figure 6d](#fig6){ref-type="fig"}). Elevated SETD2 expression correlated with better overall survival in all the subtypes of breast cancer ([Figures 6e--h](#fig6){ref-type="fig"}, ER-positive cases---229 high and 229 low; ER-negative cases---68 high and 67 low; HER-negative cases---135 high and 134 low). Combined NSD1 and SETD2 expression levels correlated with better outcome in the TCGA data set ([Figure 6i](#fig6){ref-type="fig"}) and in another public database (247 high and 314 low expression cases, [Figure 6j](#fig6){ref-type="fig"}).^[@bib44]^

Discussion
==========

In this study, we report the ability of the NF-*κ*B inhibitor DMAPT to elevate the expression of NSD1, SETD2, and KMT5C and to increase H3K36me3 and H4K20me3. Induction of NSD1, SETD2, and H3K36me3 could be recapitulated through genomic approaches that inhibited NF-*κ*B. These results reveal H3K36me3 as an epigenetic biomarker of constitutive NF-*κ*B activation in cancer.

Impact of NSD1--NF-*κ*B axis on cancer
--------------------------------------

Several epithelial and hematological malignancies show constitutive NF-*κ*B activation, which could lead to reduction in NSD1 levels.^[@bib21]^ Although NSD1 has been described as an oncogene in leukemia, this oncogenic function is only in the context of NUP98--NSD1 fusion gene where the fusion protein increases H3K36me3 specifically at the HoxA locus and increases HoxA expression.^[@bib12]^ NF-*κ*B inhibition in this context is less likely to cause upregulation of NUP98--NSD1, because NUP98 regulatory region drives this fusion gene expression. In neuroblastoma, NF-*κ*B inhibitors could potentially restore the expression of epigenetically inactivated NSD1.^[@bib9]^

In breast cancer, loss of NSD1 expression is associated with resistance to anti-estrogens.^[@bib11]^ NF-*κ*B has a significant role in anti-estrogen resistant growth of breast cancer cells and NF-*κ*B inhibitors reverse anti-estrogen resistance, which may involve induction of NSD1.^[@bib45],\ [@bib46],\ [@bib47]^ Restoration of NSD1 expression upon DMAPT treatment could also alter sensitivity to other therapies, because NSD1 is essential for BIM expression ([Figure 5](#fig5){ref-type="fig"}). BIM polymorphism and BIM levels in treatment-naive cancers determine sensitivity to receptor kinase inhibitors, particularly EGFR and mutant B-RAF signaling pathway inhibitors, glucocorticoids, and paclitaxel.^[@bib48]^

NSD1 methylates and activates non-histone targets, including the p65 subunit of NF-*κ*B.^[@bib37]^ However, NSD1 induction due to NF-*κ*B inhibition is less likely to lead to activation of NF-*κ*B target genes, because NF-*κ*B is functionally inactive due to cytoplasmic retention or degradation. NSD1 functions as a co-activator of nuclear receptors, including retinoic acid receptor.^[@bib49]^ NF-*κ*B inhibition leading to elevated NSD1 may sensitize cancer cells to retinoic acid-induced differentiation.

Impact of SETD2 repression by NF-*κ*B on cancer
-----------------------------------------------

SETD2 is frequently inactivated through mutation and/or deletion in renal, bladder, and breast cancers.^[@bib10],\ [@bib14],\ [@bib50]^ Lower expression of this gene in breast tumors correlated with poor overall survival ([Figure 6](#fig6){ref-type="fig"}). DMAPT could potentially be used to restore the expression of SETD2 in tumors, although such a treatment may not be an option in cases with mutation. Apart from histones, SETD2 interacts with p53 and induces p53-dependent pro-apoptotic genes but represses hdm2, a p53 antagonist.^[@bib51]^ Therefore NF-*κ*B inhibition in tumor cells with intact p53 may trigger a SETD2- and p53-dependent apoptosis. In this respect, DMAPT was more effective in inducing epigenetic changes in RT-4 cells with wild-type p53 compared with p53-mutant UMUC-3 cells.

NF-*κ*B-mediated repression of gene expression
----------------------------------------------

This study adds to the list of growing number of genes repressed by NF-*κ*B. We had previously demonstrated NF-*κ*B-mediated repression of GADD153.^[@bib30]^ NF-*κ*B subunit p65, when unphosphorylated at S276, recruits HDAC3 and represses transcription.^[@bib52]^ Additionally, NF-*κ*B represses transcription by targeting SP-1 and SP-3 transcription factors.^[@bib32],\ [@bib53]^ Regulatory regions of NSD1 and SETD2 contain binding sites for NF-*κ*B and SP-1, respectively. It is possible that unphosphorylated p65 occupies NSD1 regulatory region to repress transcription and DMAPT treatment or deletion of p65 leads to derepression and consequent activation. Similarly, NF-*κ*B may target SP-1 to repress SETD2. As basal levels of both NSD1 and SETD2 were higher in p65−/− cells, it is unlikely that NF-*κ*B undergoes repressor to activator switch in DMAPT-treated cells to cause induction of NSD1 and SETD2. The fact that DMAPT treatment or p65 deletion did not have global effects on histone methyltransferases or demethylases suggests that repression of NSD1 and SETD2 is a specific component of NF-*κ*B-mediated epigenetic changes.

KDM6B, which demethylates H3K27, and PHF2, which demethylates H4K20, and KDM2B, which demethylates H3K36me1, H3K36me2, and H3K4me3, have previously been reported as NF-*κ*B-inducible genes.^[@bib18],\ [@bib22],\ [@bib38]^ Although we observed NF-*κ*B-dependent expression of KDM2B, as its levels were lower in I*κ*B*α*SR-overexpressing cells compared with parental cells, we did not observe an effect of DMAPT on other KDMs tested. There are two possible explanations; one is that NF-*κ*B controls their expression in a cell type-dependent manner, and the second is that NF-*κ*B-independent activities of DMAPT cause compensatory increase in the expression of these demethylases, thus nullifying the effects of NF-*κ*B inhibition. The second possibility appears to be the case with KDM2B. Nonetheless, these observations provide explanation as to why results obtained using pharmacological inhibitors are not always compatible with results of gene ablation studies.

Evaluation of the role of NSD1 and SETD2 in DMAPT-induced BIM and p21 expression and cell death showed discordant results. Although NSD1 was required for DMAPT-induced BIM expression, NSD1 knockdown had minimum affect on growth inhibition by DMAPT. In contrast, SETD2 knockdown had no effect on DMAPT-induced BIM and p21 expression, but cells were partially resistant to DMAPT-mediated growth inhibition. At present, SETD2 downstream targets that mediate DMAPT-induced cell growth inhibition in p53-mutant cells are unknown.^[@bib51]^ Despite gaps in our understanding of this aspect of DMAPT action, data presented here suggest that NSD1 and SETD2 along with H3K36me3 can be used as biomarkers to measure the therapeutic activity of DMAPT as well as any other drugs that inhibit NF-*κ*B activity.

Materials and Methods
=====================

Cell lines
----------

UMUC-3 cells and MDA-MB-231 cells were maintained in MEM with 10% fetal bovine serum (FBS). RT-4 cells were maintained in McCoy\'s 5a medium supplemented with 2 mM L-glutamine and 10% FBS. All human cell lines used in this study have been authenticated using the STR systems for cell line identification (Promega, Madison, WI, USA) by a commercial vendor ([www.DNAcenter.com](http://www.DNAcenter.com)) in August 2012. Wild-type and p65−/− MEFs were maintained in DMEM with 10% FBS and were generous gift from Dr. Alex Hoffman (University of California, San Diego, CA, USA) and have been described.^[@bib54]^

Antibodies and western blotting analysis
----------------------------------------

Antibodies against CtBP1 (cat. no. 07-306), H3K36me3 (cat. no. CS204368), H3K9me3 (cat. no. 07-523), Acetyl H3 (cat. no. 06-599), H3K27me3 (cat. no. CS200603), H4K8 acetyl (cat. no. 06-760-MN), H4K20me1 (cat. no. 07-1570), H4K20me3 (cat. no. 07-463), H4 (cat. no. 07-108) and NSD1 (cat. no. 04-1565) were purchased from Upstate Biotechnology/Millipore (Billerica, MA, USA). Antibodies against EZH2 (cat. no. 4905) and HDAC-1 (cat. no. 2062) were purchased from Cell Signaling Technologies (Danvers, MA, USA). BIM (cat. no. 202000) antibody was purchased from Calbiochem/Millipore (Billerica, MA, USA), whereas p21 (cat. no. sc-756) and PARP-1 (cat. no. sc-7150) antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). SETD2 antibody (PA5-34934) was purchased from ThermoFisher Scientific (Waltham, MA, USA). Western blotting was performed as described previously,^[@bib39]^ and representative western blots from three or more experiments are shown. Although primary antibodies in non-histone blots were incubated in Tris-buffered saline-Tween 20 (TBS-T) with 5% non-fat milk power, histone blots with few of the primary antibodies were incubated in 5% BSA containing TBS-T.

siRNA transfection
------------------

Cells were seeded in MEM plus 10% FBS for 48 h and then transfected with 25 nM of siRNA (Dharmacon, Lafayette, CO, USA) using lipofectamine reagent. Cells were treated after 3 days of siRNA transfection with DMAPT and harvested for proteins or RNA after 24 h of DMAPT treatment.

Quantitative reverse transcription-PCR (qRT-PCR)
------------------------------------------------

Independent samples of total RNA were prepared using RNAeasy kit (Qiagen, Valencia, CA, USA). First-strand cDNA was synthesized using random hexamers and superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). qRT-PCR was performed using the SYBR green according to the manufacturer\'s protocol (Applied Biosystems, Foster City, CA, USA). Expression of *β*-actin housekeeping gene was used as an internal control for normalization between samples. Results presented are from three or more experiments, and average±S.E.M. are presented. Primer sequences used for qRT-PCR are provided in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Apoptosis assay
---------------

Apoptosis was measured using Annexin V labeling using the Apoptosis Assay Kit from Invitrogen, and the number of apoptotic cells after 24 h of DMAPT treatment was measured by flow cytometry. Both floating and adherent cells were collected and stained with Alexa Fluor-488-conjugated Annexin V and propidium iodide. Annexin V-positive cells are apoptotic, propidium iodide-positive cells are necrotic and double-positive cells are necroapoptotic.

Histone extraction
------------------

Cells were lysed with Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X 100(v/v), 2 mM phenylmethylsulfonylfluoride (PMSF), 0.02% (w/v) NaN~3~) and centrifuged at 6500 × *g* for 10 min at 4 °C to collect nuclei. The histones were subsequently extracted with 0.2 M HCl (Abcam histone extraction protocol, Cambridge, MA, USA).

Electrophoretic mobility gel shift assay
----------------------------------------

MDA-MB-231 and MEF cells were harvested in their exponential growth phase with or without TNF*α* (5 ng/ml, R&D Systems, Minneapolis, MN, USA) treatment for 15 min and assayed for NF-*κ*B and SP-1 (as a control) DNA-binding activity as described previously.^[@bib39]^ Antibodies for supershift assays were purchased from Santa Cruz (c-Rel, cat. no. sc-070) and Millipore (p65, cat. no. 06-418; p50, cat. no. 06-886).

Statistical analysis
--------------------

Results of qRT-PCR were analyzed using the GraphPad software ([www.Graphpad.com](http://www.Graphpad.com)). Analysis of variance was used to determine the *P*-values between mean measurements. A *P*-value of *\<*0.05 was deemed significant.

Analysis of public databases for prognostic relevance of NSD1 and SETD2
-----------------------------------------------------------------------

Expression array data of various bladder cancer stages were obtained from NCBI GEO (GDS1479), and average±S.D. was calculated. NSD1 expression data were from a single affymetrix probe available in the data set, whereas average from three probes was used for SETD2. For breast cancer, analysis of TCGA data set^[@bib55]^ for NSD1 and SETD2 expression is presented although similar analysis using a public data set with gene expression pattern in tumors of 1809 breast cancer patients yielded similar results.^[@bib44]^
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CtBP1

:   C-terminal-binding protein 1

DMAPT

:   dimethylaminoparthenolide

GEO

:   gene expression omnibus

H3K27me3

:   histone 3 lysine 27 trimethylation

H3K36me3

:   histone 3 lysine 36 trimethylation

H4K20me3

:   histone 4 lysine 20 trimethylation

HDAC-1

:   histone deacetylase 1

I*κ*B*α*SR

:   inhibitor-of-kappaB alpha super-repressor

JNK

:   c-Jun N-terminal kinase

KMT

:   lysine methyltransferases

KDM

:   lysine demethylases

MEF

:   mouse embryonic fibroblast

NF-*κ*B

:   nuclear factor-kappaB

NSD1

:   nuclear receptor-binding SET domain protein 1

NUP98

:   nucleoporin 98 kDa

PARP

:   poly-(ADP-ribose) polymerase

PHF2

:   PHD finger protein 2

qRT-PCR

:   quantitative reverse transcription-PCR

SETD2

:   SET domain containing 2

TBS-T

:   Tris-buffered saline-Tween 20

TCGA

:   The Cancer Genome Atlas

TNF*α*

:   tumor necrosis factor alpha
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![The effect of DMAPT on the expression of epigenetic regulators and on histones. (**a**) DMAPT reduced the levels of EZH2, HDAC-1, CtBP1, and PARP1 in a cell type-dependent manner. Cells were treated with 10 *μ*M DMAPT for the indicated time, and cell lysates were subjected to western blotting. Representative data from two or more experiments are shown. (**b**) DMAPT induced the expression of p21 and BIM. (**c**) The effect of DMAPT treatment on histone modifications. H3K36me3 blots were reprobed with histone H4 as a quality control](cddis2014569f1){#fig1}

![The role of NF-*κ*B in DMAPT-mediated histone modifications. (**a**) NF-*κ*B DNA-binding activity in MDA-MB-231 with or without I*κ*B*α*SR overexpression and in MEFs with and without p65 deletion. Cells were incubated with or without TNF*α* for 15 min, and NF-*κ*B and SP-1 (as a control) DNA-binding activity was measured by electrophoretic mobility gel shift assay. Antibody supershift assay with extracts from wild-type and p65−/− cells is shown in the right side (lanes 13--20). (**b**) The effect of I*κ*B*α*SR overexpression on DMAPT-induced histone modification in MDA-MB-231 cells. Basal H3K36me3 was higher in cells with I*κ*B*α*SR overexpression compared with parental cells with empty lentivirus (pCL6), and it was further increased by DMAPT. (**c**) P65−/− MEFs showed elevated basal H3K36me3 but not H4K20me3 compared with wild-type MEFs. DMAPT increased H3K36me3 and H4K20me3 in wild-type MEFs](cddis2014569f2){#fig2}

![DMAPT induced histone H3K36 methyltransferases NSD1 and SETD2. (**a**) The effect of DMAPT on NSD1 expression. Cells were treated with 10 *μ*M DMAPT for 12 h, and qRT-PCR was performed to measure NSD1 mRNA. Average±S.E.M. from biological replicates is shown. Asterisk in this and subsequent figures denotes statistically significant differences with a *P*-value of \<0.05. (**b**) The effect of DMAPT on SETD2 expression. Basal SETD2 level was significantly higher in p65−/− cells compared with wild-type cells. (**c**) The effect of DMAPT on NSD1 and SETD2 proteins in wild-type and p65−/− MEFs. (**d**) DMAPT reduced CXCL1 mRNA in RT-4 and UMUC-3 cells. (**e**) The effect of p65NLS50 expression on NSD1 and SETD2 expression in p65−/− cells. Cells were transfected with empty vector pcDNA3 or p65NLS50 vector (10 *μ*gs), and RNA was analyzed for NSD1 and SETD2 levels 48 h after transfection. (**f**) H3K36me3 and H4K20me3 levels in pcDNA3- and p65NLS50-transfected cells. Experiments were done as in panel (**e**). (**g**) DMAPT (10 *μ*M) reduced PARP-1 in wild-type but not p65−/− cells. (**h**) Wild-type but not p65−/− cells were sensitive to DMAPT-induced apoptosis. Cells were treated with the indicated concentration of DMAPT for 24 h, and apoptosis was measured using Annexin V labeling. Representative results are shown](cddis2014569f3){#fig3}

![DMAPT increased histone H4K20 trimethyltransferase KMT5C in a cell type-dependent but NF-*κ*B-independent manner. (**a**) KMT5C expression in DMAPT-treated cells. Cells were treated with DMAPT for 6 h. Note that I*κ*B*α*SR overexpression had minimum effect on KMT5C expression in MDA-MB-231 cells. (**b**) NF-*κ*B activity is required for KDM2B expression in MDA-MB-231 but not in MEFs. I*κ*B*α*SR overexpression caused significant drop in basal KDM2B levels in MD-MB-231 cells, whereas p65 knockout did not have an effect on its expression in MEFs](cddis2014569f4){#fig4}

![NSD1 is essential for DMAPT-induced BIM and p21 expression. (**a**) BIM and p21 levels in untreated and DMAPT-treated UMUC-3 cells additionally transfected with siRNA against luciferase as a negative control, NSD1, SETD2, or both NSD1 and SETD2. Cells were treated after 3 days of siRNA transfection with DMAPT and harvested for proteins after 24 h of DMAPT treatment. NSD1 siRNA prevented DMAPT-induced BIM and p21. For unknown reasons, basal p21 levels in NSD1 siRNA-treated cells showed remarkable experimental variability in UMUC-3 cells. Densitometry values show comparison between untreated controls and DMAPT-treated cells with respective controls normalized to 1. (**b**) NSD1 and SETD2 mRNA levels in siRNA-transfected cells. Respective mRNAs were measured 4 days after siRNA transfection. (**c**) SETD2 is required for DMAPT-mediated growth inhibition. Cells were plated in a 96-well plate and treated with DMAPT for 48 h. Cell proliferation was measured using BrDU-incorportation ELISA](cddis2014569f5){#fig5}

![Prognostic value of NSD1 and SETD2 in cancer. (**a**) Levels of NSD1 in normal urothelium and various stages of bladder cancer. NCBI GEO data set GDS1479, which contains NSD1 expression levels (one probe set) in normal urothelium and different stages of bladder cancer, was used to generate this figure. (**b**) Levels of SETD2 in normal urothelium and various stages of bladder cancer. Data were generated using the same data set as in panel (**a**) except that signals were average of three probes that measured SETD2 mRNA. (**c**--**j**) Prognostic value of NSD1, SETD2, or combination in different subtypes of breast cancer. Public databases created by us^[@bib43]^ (**c**--**i**) and others^[@bib44]^ (**j**) were used to generate these figures](cddis2014569f6){#fig6}

###### Summary of the effects of DMAPT treatment, I*κ*B*α*SR overexpression, and p65 depletion on epigenetic markers and the expression of epigenetic regulators

              DMAPT            I*κ*B*α*SR            P65−/−
  ---------- ------- ------------------------------ --------
  H3K36me3     Yes                Yes                 Yes
  H4K20me3     Yes                 No                  No
  NSD1         Yes    ?[a](#t1-fn1){ref-type="fn"}    Yes
  SETD2        Yes    ?[a](#t1-fn1){ref-type="fn"}    Yes
  KMT5C        Yes                 No                  No
  KDM2B        No                 Yes                  No

Trend of an effect but did not reach statistical significance
